20-F/A XBRL

AMENDMENT NO. 2 TO FORM 20-F

Company: Altamira Therapeutics Ltd.
Filed: July 1, 2024
Period of Report: December 31, 2023
Accession Number: 0001213900-24-057548

View Document ↗ View on SEC.gov ↗